On June 30, 2025, Cyclacel Pharmaceuticals held its Annual Meeting where shareholders re-elected five directors and approved an amendment to increase shares for the equity incentive plan by over 4.28 million shares. Additionally, they approved the compensation for executive officers by 99.95%.